Resident by Hernan Cattaneo

BioCentury 389 - Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.

For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

00:00

Epizode

27 јул. 2026

20 јул. 2026

15 јул. 2026

13 јул. 2026

06 јул. 2026

29 јун. 2026

22 јун. 2026

15 јун. 2026

10 јун. 2026

08 јун. 2026

01 јун. 2026

26 мај 2026

18 мај 2026

12 мај 2026

11 мај 2026

04 мај 2026

27 апр. 2026

22 апр. 2026

20 апр. 2026

13 апр. 2026

06 апр. 2026

01 апр. 2026

30 мар. 2026

23 мар. 2026

16 мар. 2026

13 мар. 2026

09 мар. 2026

02 мар. 2026

23 феб. 2026

17 феб. 2026

09 феб. 2026

02 феб. 2026

26 јан. 2026

22 јан. 2026

20 јан. 2026

15 јан. 2026

12 јан. 2026

05 јан. 2026

29 дец. 2025

15 дец. 2025

08 дец. 2025

01 дец. 2025

24 нов. 2025

21 нов. 2025

20 нов. 2025

17 нов. 2025

12 нов. 2025

10 нов. 2025

03 нов. 2025

31 окт. 2025

Resident by Hernan Cattaneo

Epizode

Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data

Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson

Ep. 376 - M&A momentum: 3Q public markets preview

Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

Ep. 374 - Parkinson's deep dive & FDA trial reforms

Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

Ep. 371 - Moving faster at the academia-industry interface

Ep. 370 - Calmer waters for FDA; Servier, Lilly deals

Ep. 369 - ASCO advances, China innovation & U.S. science under threat

Ep. 368 - ASCO Preview, China Policy, ADC Linkers

Ep. 367 - FDA, obesity targets and the rise of DACs

Ep. 366 - Europe's need for speed: Bio€quity takeaways

Ep. 365 - Thin ice for Makary, redosing AAVs

Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies

Ep. 363 - New targets at AACR, biopharma deals, Kurma fund

Ep. 362 - AACR: Data and de-risking

Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers

Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

Ep. 358 - Europe's biotech challenge

Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision

Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN

Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline

Ep. 354 - East-West Summit Takeaways

Ep. 353 - Prasad Departure and Future of Fibrosis Therapies

Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight

Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint

Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA

Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch

Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos

Ep. 346 - 2026 Public Markets Preview

Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN

Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation

Ep. 343 - JPM Deals, Policy Outlook, Approval Trends

Ep. 342 - 2026 Biotech Kickoff

Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI

Ep. 340 - Obesity Data, Kymera & FDA Survey Results

Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult

Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, Cell, Gene Therapy Funding

Ep. 337 - FDA’s Moving Goalposts & China’s Innovation Arc

Ep. 336 - Cautious Optimism and M&A Momentum

Ep. 335 - Neurology's Coming Inflection Point

Ep. 334 - Pazdur’s New FDA Role, SITC & China RNAi

Ep. 333 - Is This Korea’s Biotech Moment?

Ep. 332 - Obesity in Focus. Plus: What’s Next for FDA

Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster

Ep. 330 - China's Innovation Moment